Edding Genor Group Holdings Limited (SEHK: 6998)
Salud · Biotecnología · CN
1,55 HK$
+1,97 % hoy · -48,3 % 1 año
Edding Genor Group Holdings Limited (SEHK: 6998) opera en la industria de biotecnología dentro del sector salud. Su valor en bolsa es de 394,79 M $ y tiene 1499 empleados.
En los últimos doce meses la acción ha bajado un 48,3 % y ha cotizado entre 1,42 y 3,64.
Tweenvest puntúa a Edding Genor Group Holdings Limited en cuatro factores: calidad 82/100, valor 94/100. Su punto más fuerte es valor.
Evolución de la cotización de 6998
Cifras clave
- Capitalización
- 394,79 M $
- Ingresos (últ. 12 m)
- 327,50 M $
- PER
- 15,01
- BPA
- 0,08
- Rent. por dividendo
- —
- Beta (5 años)
- 0,99
- Máximo 52 semanas
- 3,64 HK$
- Mínimo 52 semanas
- 1,42 HK$
- Volumen medio (3 m)
- —
- Acciones en circulación
- 2,00 mil M
- Empleados
- 1499
- Próximos resultados
- —
Sobre Edding Genor Group Holdings Limited
Edding Genor Group Holdings Limited operates as a biopharmaceutical enterprise, concentrating its efforts on the research, development, and commercialization of therapeutic agents for oncology and autoimmune disorders, both within China and globally. Its key investigational medicines include GB242, an infliximab (Remicade) biosimilar. This drug is purposed for the treatment of various conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric Crohn's disease, and fistulizing Crohn's disease. Another prominent candidate is GB491 (lerociclib), an oral CDK4/6 inhibitor currently undergoing Phase III clinical trials for hormone receptor-positive (HR+)/HER2- breast cancer. Additionally, GB492, a stimulator of interferon genes (STING) agonist, is in Phase 1/2 clinical development, with expectations of synergistic effects when combined with GB226 for solid tumor treatment. The company's pipeline also encompasses GB221, a HER2 monoclonal antibody (mAb) designed to mimic trastuzumab (Herceptin); geptanolimab (GB226), a novel PD-1 mAb; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb, which is in Phase I clinical trials; and GB261, also in Phase I clinical trials for B-cell non-Hodgkin Lymphoma. Furthermore, its product candidates in clinical trials for cancer treatment include GB262, GB264, GB265, and GB266. Founded in 2007, the firm maintains its headquarters in Shanghai, China.
- ISIN
- KYG3871A1004
- Fundada en
- 2001
- Cotiza desde
- 7 oct 2020
- Bolsa
- The Stock Exchange of Hong Kong Ltd.
- Divisa
- HKD
Otras empresas de biotecnología
| Empresa | Capitalización | Precio | Día |
|---|---|---|---|
| Jacobio Pharmaceuticals Group Co., Ltd.SEHK: 1167 | 405,32 M $ | 4,07 HK$ | -2,28 % |
| Candel Therapeutics, Inc.NasdaqGM: CADL | 402,43 M $ | 5,13 $ | -3,57 % |
| Blau Farmacêutica S.A.BOVESPA: BLAU3 | 400,67 M $ | 9,78 R$ | -0,41 % |
| SanBio Company LimitedTSE: 4592 | 395,95 M $ | 808,00 ¥ | 0,00 % |
| Avalo Therapeutics, Inc.NasdaqCM: AVTX | 390,31 M $ | 6,75 $ | +0,75 % |
| Pharmicell Co., Ltd.KOSE: A005690 | 389,17 M $ | 8670,00 ₩ | +1,05 % |
| Landfar Bio-medicine Co., LtdSZSE: 000504 | 388,11 M $ | 7,85 CN¥ | -4,96 % |
| Beijing Luzhu Biotechnology Co., Ltd.SEHK: 2480 | 387,91 M $ | 15,30 HK$ | 0,00 % |